HBPCF (Helix BioPharma) EV-to-EBIT : -3.91 (As of Apr. 15, 2025)

Helix BioPharma EV-to-EBIT Chart

Helix BioPharma Annual Data
	Trend	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22	Jul23	Jul24
EV-to-EBIT		Get a 7-Day Free Trial					-8.00	-12.26	-4.87	-7.12	-5.97

Helix BioPharma Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
EV-to-EBIT	Get a 7-Day Free Trial															-7.28	-8.12	-5.97	-4.28	-4.77

Competitive Comparison of Helix BioPharma's EV-to-EBIT

For the Biotechnology subindustry, Helix BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's EV-to-EBIT falls into.

Helix BioPharma EV-to-EBIT Calculation

Helix BioPharma's EV-to-EBIT for today is calculated as:

Helix BioPharma's current Enterprise Value is $27.83 Mil.
Helix BioPharma's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma  (OTCPK:HBPCF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Helix BioPharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

Helix BioPharma's Enterprise Value for the quarter that ended in Jan. 2025 was $22.73 Mil.
Helix BioPharma's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description